Journal article

What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy

Martha Hickey, Katrina M Moss, Gita D Mishra, Efrosinia O Krejany, Susan M Domchek, John D Wark, Alison Trainer, Robert A Wild

GYNECOLOGIC ONCOLOGY | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2021

Abstract

OBJECTIVE: To prospectively measure cardiometabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomy (RRBSO) compared to a similar age comparison group, and the effects of Hormone Therapy (HT) on cardiometabolic risk. METHODS: Prospective observational study of 95 premenopausal women planning RRBSO and 99 comparisons who retained their ovaries. At baseline and 12 months, blood pressure (BP), Body Mass Index (BMI), waist and hip circumference, fasting total, HDL and LDL cholesterol, triglycerides, high-sensitivity C-reactive protein, glucose and insulin were measured and HOMA-IR was calculated. Chi-square tests, t-tests and adjusted logistic regression models w..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by Susan G. Komen organization


Awarded by NHMRC Practitioner Fellowship


Awarded by NHMRC Principal Research Fellowship


Funding Acknowledgements

This research was supported by Register4 through its members'participation in research and/or provision of samples and information (register4.org.au) .r In Australia this study was supported by public funding provided by the National Health and Medical Research Council of Australia (NHMRC; Grant #APP1048023) , and by philanthropic funding provided by The Royal Women's Hospital (Melbourne, Australia) , The Women's Foundation (Melbourne, Australia) , Australia New Zealand Gynaecological Oncology Group (ANZGOG, Sydney, Australia) and the Westmead Hospital Familial Cancer Service (Sydney, Australia) . In the USA this study was supported by philanthropic funding provided by the Basser Center for BRCA and the Susan G. Komen organization (Grant #SAC150003) . None of the funding agencies had a role in the design or conduct of the study, nor the collection, management, analyses or interpretation of the data, nor the preparation or approval of this manuscript.r MH is supported by a NHMRC Practitioner Fellowship (ID #1058935) . GDM is supported by a NHMRC Principal Research Fellowship (ID #APP1121844) . SMD is supported by the Susan G. Komen organization.r We are grateful to the women who generously gave of their time to participate in this study and to the following people who assisted with participant recruitment and study management: David Wrede, Orla McNally and Deborah Neesham (The Royal Women's Hospital, Melbourne, Australia) , Judy Kirk and Alison Brand (Westmead Hospital, Sydney, Australia) , Lesley Andrews and Leon Botes (Prince of Wales Hospital, Sydney, Australia) , Bettina Meiser (University of Sydney, Sydney, Australia) , Mariana De Sousa (University of Technology, Sydney, Australia) , Heather Symecko (University of Pennsylvania, Philadelphia, USA) , Sue Shanley, Gillian Mitchell and Mary Shanahan (Peter MacCallum Cancer Centre, Melbourne, Australia) , Trevor TejadaBerges and Masako Dunn (Chris O'Brien Lifehouse, Sydney, Australia) , L. Jane McNeilage and Marion Harris (Monash Medical Centre, Melbourne, Australia) , Geoffrey Lindeman (The Royal Melbourne Hospital, Melbourne, Australia) , Peter Grant (Mercy Hospital for Women, Melbourne, Australia) and Nipuni Gamage (University of Melbourne, Melbourne, Australia) . Thanks also to MaryAnn Davey (Monash University, Melbourne, Australia) and Sabine Braat (University of Melbourne, Melbourne, Australia) for the provision of preliminary advice and support with statistical methodology, modelling and analysis.